Biostax Corp (BTAX)

[locicat1]

Good question! If you look back at the 8-K coverage of the announcement of the receipt of the purported follow up minutes/guidance from the purported FDA Meeting in January, 2018, the framing was IMUN/Cytocom--there was wording, as I recall, that stated that IMUN was attending the purported Meeting on "behalf of Cytocom" and hence the IMUN/Cytocom framing. I am just guessing here, but since the original IND with the FDA most probably still sits with IMUN, it was probably that situation leading to a joint IMUN/Cytocom purported presentation at the FDA. Thus if any Phase 2/3 studies are to start with the FDA I believe IMUN would be absolutely obliged to announce such to the public.